Wells score for pulmonary embolism (also searched with alternate eponym spelling Wells criteria for pulmonary embolism, ICD-10: I26.9) is a validated clinical prediction tool utilized to stratify patients with suspected acute pulmonary embolism into pretest probability categories 1,2. Developed to streamline diagnostic pathways and avoid unnecessary imaging exposure, the Wells score assigns weighted numerical points based on clinical signs, symptoms, and historical risk factors 3,4. When combined with highly sensitive D-dimer assays or advanced computed tomography pulmonary angiography, the score forms the bedrock of safe, evidence-based diagnostic algorithms in emergency and inpatient settings 5,6.

Etiology & Risk Factors

  • Virchow Triad Components: Venous stasis (prolonged immobilization, paralysis, long-distance travel), endothelial injury (recent trauma, surgery, indwelling central venous catheters), and hypercoagulability (malignancy, inherited or acquired thrombophilias) 1,2.
  • Inherited Thrombophilias: Factor V Leiden mutation, prothrombin gene mutation (G20210A), antithrombin III deficiency, and deficiencies of protein C or protein S.
  • Acquired Hypercoagulable States: Active malignancy, antiphospholipid syndrome, nephrotic syndrome, inflammatory bowel disease, and pregnancy or the postpartum period 7.
  • Iatrogenic & Lifestyle Factors: Oral contraceptive pills, hormone replacement therapy, selective oestrogen receptor modulators, and recent major surgical procedures or orthopaedic operations 1,2.
  • Prior Venous Thromboembolism: A documented personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE) significantly increases the baseline recurrence risk 6.

Pathophysiology

Pulmonary embolism begins when a thrombus, most commonly originating from the proximal deep veins of the lower extremities (iliac, femoral, or popliteal veins), dislodges and embolises through the right heart chambers into the pulmonary arterial tree 1,6. The mechanical obstruction of pulmonary arterial branches causes an immediate increase in pulmonary vascular resistance (PVR) 3. This abrupt elevation in right ventricular (RV) afterload leads to RV dilation, increased wall tension, and myocardial oxygen demand 6. Concurrently, the septum shifts leftward, impairing left ventricular filling and causing a subsequent drop in systemic cardiac output and systemic arterial pressure 5,6. Gas exchange is severely disrupted by ventilation-perfusion (V/Q) mismatch, where unperfused ventilated lung units act as alveolar dead space, frequently accompanied by hypoxaemia driven by intrapulmonary shunting and low mixed venous oxygen saturation 1,6.

Wells score for pulmonary embolism — Pathophysiological Cascade & Clinical Flowchart 1 Virchow Triad Initiation Venous stasis, endothelial injury, or hypercoagulability precipitates thrombus formation, typically originating in the deep veins of the lower extremities. 2 Thrombus Embolization A portion of the deep venous thrombus detaches, travels through the inferior vena cava and right heart chambers, and lodges in the pulmonary arterial vasculature. 3 Haemodynamic Compromise Mechanical obstruction increases pulmonary vascular resistance, elevating right ventricular afterload and precipitating acute right ventricular strain or failure. 4 Gas Exchange Impairment Ventilation-perfusion mismatch develops alongside alveolar hyperventilation, resulting in hypoxaemia and an increased alveolar-arterial oxygen gradient. 5 Therapeutic Anticoagulation Administration of direct oral anticoagulants or low-molecular-weight heparin halts clot propagation, permitting endogenous fibrinolysis to restore pulmonary perfusion.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Sudden-onset dyspnea at rest or with exertion (the most frequent symptom), pleuritic chest pain exacerbated by deep inspiration, cough, haemoptysis, unilateral lower extremity pain and swelling suggestive of DVT, and syncope or presyncope in massive or submassive embolic events 5,6.
  • Physical Examination & Named Clinical Signs: Tachypnea (respiratory rate >20 breaths/min), tachycardia, low-grade fever, an accentuated pulmonic component of the second heart sound (P2), an RV heave or gallop rhythm (S3 or S4 gallop), and clinical signs of deep vein thrombosis such as calf asymmetry, tenderness, or pitting oedema 1,6. Massive pulmonary embolism may manifest with jugular venous distention, hypotension, cyanosis, and obstructive shock 6.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationComputed tomography pulmonary angiography (CTPA) demonstrating definitive intravascular filling defects within the main, lobar, segmental, or subsegmental pulmonary arteries.
Laboratory PanelElevated plasma D-dimer levels (via quantitative ELISA assay; highly sensitive but non-specific), elevated cardiac troponins (T or I) indicating myocardial strain, and elevated natriuretic peptides (BNP or NT-proBNP) reflecting right ventricular stretch.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography is often normal or displays non-specific findings such as atelectasis, pleural effusion, elevated hemidiaphragm, or peripheral wedge-shaped opacities (Hampton hump); lower extremity compression ultrasonography frequently reveals incompressible deep veins diagnostic of DVT.
ECG / Histopathology / ProceduralElectrocardiogram classically displays sinus tachycardia, an S1Q3T3 pattern (deep S wave in lead I, Q wave in lead III, and inverted T wave in lead III), incomplete or complete right bundle branch block, and right axis deviation; arterial blood gas analysis demonstrates acute respiratory alkalosis with hypoxaemia and an increased alveolar-arterial oxygen gradient.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Clinical signs and symptoms of DVTObjective evidence of lower limb swelling and pain with tenderness along the deep venous system: 3.0 points
Alternative diagnosis less likely than PEClinician judges that an alternative diagnosis is less likely than pulmonary embolism: 3.0 points
Heart rate > 100 beats per minuteTachycardia documented upon clinical evaluation: 1.5 points
Immobilization or surgery within the past 4 weeksBed rest for >3 days or major surgery requiring general anaesthesia within the past month: 1.5 points
Previous, objectively diagnosed DVT or PEA documented prior episode of venous thromboembolism: 1.5 points
HaemoptysisPresence of blood-tinged sputum or coughing up blood: 1.0 point
Malignancy (treated within 6 months or palliative)Active cancer receiving treatment, currently active, or under palliative care: 1.0 point
Traditional Interpretation ThresholdsScore >4 indicates PE likely (proceed to CTPA); Score ≤4 indicates PE unlikely (proceed to D-dimer assay to safely rule out PE). Alternatively, a simplified score uses thresholds of 0 for unlikely and ≥2 for likely.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Acute Coronary Syndrome / Myocardial InfarctionSubsternal pressure-like chest pain radiating to the jaw or arm, dynamic ST-segment and T-wave changes on ECG, and elevated cardiac biomarkers without typical V/Q mismatch or CTPA filling defects.
PneumoniaFever, productive cough with purulent sputum, focal lung consolidation on chest radiography, and elevated inflammatory markers (procalcitonin, CRP).
Acute Heart Failure ExacerbationProgressive dyspnea, orthopnoea, paroxysmal nocturnal dyspnea, bilateral pedal oedema, pulmonary congestion on chest X-ray, and elevated BNP without primary vascular occlusion.
Aortic DissectionSudden-onset, severe tearing or ripping chest or back pain often radiating to the interscapular region, pulse deficits, widened mediastinum on chest X-ray, and definitive diagnosis via dedicated aortic CTA.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Assess airway, breathing, and circulation immediately; administer supplemental oxygen if oxygen saturation drops below 92%; initiate aggressive fluid resuscitation cautiously or administer vasopressors (such as norepinephrine) for patients presenting with haemodynamic instability and obstructive shock 6.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Initiate immediate anticoagulation while diagnostic workup is pending if clinical suspicion is high. Preferred oral agents include apixaban (10 mg PO BID for 7 days, followed by 5 mg PO BID) or rivaroxaban (15 mg PO BID for 21 days, followed by 20 mg PO daily). Alternatively, initiate parenteral anticoagulation with low-molecular-weight heparin (enoxaparin 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily) or unfractionated heparin (IV bolus of 80 units/kg followed by continuous infusion titrated to an aPTT 1.5 to 2.0 times control) bridged to vitamin K antagonists (warfarin targeted to an INR of 2.0 to 3.0) 2,3.
  • Surgical / Interventional Indications: Systemic thrombolytic therapy (e.g., alteplase 100 mg IV infusion over 2 hours) or catheter-directed thrombolysis/thrombectomy is indicated for massive pulmonary embolism presenting with persistent hypotension or cardiogenic shock, provided there are no absolute contraindications 6. Surgical embolectomy is reserved for patients with massive PE in whom thrombolysis fails or is contraindicated 6.

Complications & Prognosis

  • Acute & Chronic Complications: Acute right ventricular failure, cardiogenic shock, recurrent venous thromboembolism, major bleeding secondary to anticoagulant therapy, and chronic thromboembolic pulmonary hypertension (CTEPH) resulting from unresolved fibrotic obstruction of the pulmonary vasculature 3,6.
  • Prognostic Factors: Prognosis is directly related to the extent of pulmonary vascular obstruction, baseline cardiopulmonary reserve, magnitude of right ventricular strain, and prompt initiation of therapeutic anticoagulation 6. Early risk stratification utilising the Wells score and biomarkers significantly reduces morbidity and mortality in acute presentations 3,6.